NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

SciSparc Ltd. (SPRC) Stock Analysis

SciSparc Ltd. (SPRC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SPRC

$5.29

+$0.16 (+3.12%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPRC with… →

SPRC Key Statistics

As of Sep 4, 2026
Trading
Open
$5.17
Previous Close
$5.13
Day's Range
5.15–5.44
52-Week Range
2.98–80.10
Volume
27.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.44
Valuation
Market Cap
$3.07M
P/E Ratio
0.05
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.59
EPS (ttm)Profit attributable to each share over the last twelve months.
101.13
Financials (FY)
Revenue (FY)
$856.00K−34.46%
Net Income (FY)
−$12.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
580.97K
1-Year Return
−72.40%
Dividend and dates
Avg Volume
192.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SPRC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−56.78%
2025−82.01%
2024−92.62%
2023−75.17%
2022−87.87%
2021 (partial year)+38.44%

As of September 4, 2026.

SPRC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$856.00K−$12.18M−1422.8%
2024$1.31M−$6.28M−481.2%
2023$2.88M−$5.12M−177.9%
2022$1.35M−$2.59M−192.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$856.00K$631.00K−$8.75M−$12.18M−1422.8%
2024$1.31M$506.00K−$7.24M−$6.28M−481.2%
2023$2.88M$2.20M−$5.77M−$5.12M−177.9%
2022$1.35M$1.03M−$8.29M−$2.59M−192.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SPRC Valuation vs Biotechnology Median

Median of 656 stocks
MetricSPRCBiotechnology medianvs median
P/E0.0512.570.0x the median
P/S ratio3.5915.260.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values SciSparc Ltd. (SPRC) at $3.07M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3.

The 52-week range on file runs from $2.98 to $80.10. SPRC last closed at $5.29 on September 4, 2026. That is +$0.16 (+3.12%) against the previous close. The latest close sits 77.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $856.00K. Against the prior fiscal year total of $1.31M, that is a change of −34.46%. The same year closed with a net loss of $12.18M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 101.13.

Across the 4 fiscal years on file, revenue moves from $1.35M in 2022 to $856.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 0.05 times earnings. That is 0 times the Biotechnology median of 12.57. The price-to-sales ratio is 3.59. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −72.40%. Across 5 years the annualized return works out at −82.19%. The reported beta is 2.44. Daily returns over the trailing 5 years annualize to a volatility of 189.47%.

Growth & Income

No dividend is on file for SPRC.

Across the complete calendar years on file, 2023 returned −75.17% and 2024 returned −92.62%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −56.78% year to date.

Peer Comparison

SciSparc Ltd. (SPRC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SciSparc Ltd. SPRC $3.07M 0.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. SciSparc Ltd. trades at a P/E of 0.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About SciSparc Ltd.

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Visit website →